OmniSeq Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced that it has entered into an exclusive distribution agreement with LabCorp, a leading global life sciences company, for the distribution of its Immune Report CardSM and OmniSeq ComprehensiveSM clinical assays.
Immune Report Card is a first-in-kind comprehensive immune profiling test designed to inform oncologists regarding checkpoint inhibitor (CPI) treatment decisions.
OmniSeq Comprehensive is a 144-gene, pan-cancer, next-generation sequencing tumor profiling diagnostic panel to guide oncology treatment decision-making.
The tests, performed by OmniSeq, will be exclusively offered by LabCorp to U.S.-based physicians through Integrated Oncology, a member of the LabCorp Specialty Testing Group, and globally to biopharmaceutical customers through Covance Drug Development.
The financing will be used to conduct ongoing retrospective and prospective clinical trials and to generate further evidence of the clinical utility of OmniSeq’s comprehensive genomic and immune profiling services.
Crosstree Capital Partners acted as exclusive financial advisor to OmniSeq Inc.